Extended Phenytoin Sodium
Brand Names: Phenytek, Dilantin
Methodology & AI Transparency ⓘ
Extended Phenytoin Sodium Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage phenytek: ® capsules (extended phenytoin sodium capsules) are indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery.
- 2 Real-world patient consensus: Zero-PHI community consensus: 89% favorable across 16 logged regimens (Phenytek, Dilantin).
- 3 Typical cash cost range: 30-day cash pricing ranges from $65.26 discount cash to $159.89 walk-in retail (NADAC $1.4015/unit).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Extended Phenytoin Sodium): nausea (8.1%), headache (8%), dizziness (6.6%).
Ask our AI Specialists anything about Extended Phenytoin Sodium
Extended Phenytoin Sodium Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage phenytek: ® capsules (extended phenytoin sodium capsules) are indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. PHENYTEK ® CAPSULES are indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. ( 1 )
12.1 Mechanism of Action The precise mechanism by which phenytoin exerts its therapeutic effect has not been established but is thought to involve the voltage-dependent blockade of membrane sodium channels resulting in a reduction in sustained high-frequency neuronal discharges.
Clinical clearance of Extended Phenytoin Sodium (Anti-epileptic Agent) relies on phase i cyp2c9, cyp2c19 hepatic clearance and subsequent renal metabolite filtration with a Steady-state plasma equilibrium reached over 3–7 hour t½ intervals for Extended Phenytoin Sodium half-life; patients absorbing at Approximately 60% to 72% enteral uptake across labeled Extended Phenytoin Sodium strengths bioavailability typically observe target onset around maximum serum exposure occurs 2–5 hours after extended phenytoin sodium dosing.
FDA clinical labeling for Extended Phenytoin Sodium restricts administration in 4 contraindications phenytek ® capsules are contraindicated in patients with:; a history of hypersensitivity to phenytoin, its inactive ingredients, or other hydantoins .; reactions have included angioedema. across 100 mg/1 Capsule, Extended Release, 200 mg/1 Capsule, Extended Release, 30 mg/1 Capsule, Extended Release, with self-reported patient tracking dominated by nausea (8.1% of reports), headache (8% of reports), dizziness (6.6% of reports).
Rifampin or anticonvulsant inducers can diminish Extended Phenytoin Sodium systemic exposure and clinical response.
Co-prescribing strong CYP2C9 inhibitors or inducers can modify Extended Phenytoin Sodium metabolic elimination kinetics.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- 4 CONTRAINDICATIONS PHENYTEK ® capsules are contraindicated in patients with:
- A history of hypersensitivity to phenytoin, its inactive ingredients, or other hydantoins .
- Reactions have included angioedema.
Logged Side-Effect Incidence (16 Reports)
Extended Phenytoin Sodium Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Extended Phenytoin Sodium)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Metformin extended-release vs. Metformin immediate-release: Which Works Better for Adults with type 2 diabetes? MXR was associated with statistically worse but likely clinically similar HbA1c lowering and minimal improvement. Diabetes research and clinical practice • 2021-08-15 • Meta-Analysis | N = 2,609 | 94/100 | PMID 33887354 ↗ |
| New Insights on Predicting efficacy of viloxazine extended-release treatment in adults with ADHD: What a 354-Participant Study Found The ROC curves indicated that data collected up to Week 2 were sufficient to accurately predict treatment response at Week 6 with 68% positive predictive power, 80% sensitivity, and 74% specificity. Psychiatry research • 2022-12-15 • Phase III Randomized Trial | N = 354 | 93/100 | PMID 36375329 ↗ |
| New Insights on Benefits and safety of a novel, extended-release rivastigmine transdermal patch: What a 362-Participant Study Found However, analysis of the per-protocol set demonstrated a. Journal of Alzheimer's disease : JAD • 2026-01-15 • Phase III Randomized Trial | N = 362 | 93/100 | PMID 41364455 ↗ |
| New Insights on Effect of palbociclib plus letrozole on patient-reported health-related quality: What a 444-Participant Study Found This extended follow-up analysis of PROs in PALOMA-2 shows continued QoL maintenance for patients with ER+/HER2- mBC receiving long-term palbociclib plus letrozole treatment. ESMO open • 2025-04-15 • Phase III Randomized Trial | N = 444 | 93/100 | PMID 40107156 ↗ |
| New Insights on Benefits and safety of bupropion hydrochloride extended-release versus: What a 538-Participant Study Found Results from this study demonstrated that the efficacy of bupropion XL was non-inferior to that of escitalopram in Chinese patients with MDD. Journal of affective disorders • 2019-10-01 • Randomized Controlled Trial | N = 538 | 93/100 | PMID 31301615 ↗ |
Extended Phenytoin Sodium Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.4015/unit (~$42.05/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $159.89 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 16 Anonymous DotMD Community Micro-Logs | $65.26 / mo | View logs ↓ |
Extended Phenytoin Sodium Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Extended Phenytoin Sodium RxNorm Concept ID | 855861 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.4015 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $159.89 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $65.26 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 89.00% Worth It (16 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Extended Phenytoin Sodium Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Extended Phenytoin Sodium: FDA labeling (2024-10-15, NDC 0378-2670), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Extended Phenytoin Sodium community threads and patient logs by age, biological sex, dosage, and treatment duration.